From evidence to clinical practice; age-appropriate dosing

The paediatric population lacks extensive clinical trials, resulting in a reliance on extrapolated adult data for paediatric pharmacotherapy. However, age-related pharmacokinetic changes necessitate tailored age-appropriate dosing strategies to ensure safe and effective dosing.

Model-informed dosing (MID) can provide objective evidence on expected drug exposure in different age groups, assess age-related variability, and allow prospective comparison of dosing strategies. Ultimately, it supports evaluation of appropriate dose regimens when it maintains drug levels within the therapeutic range and can be used by the Dutch Paediatric Formulary as supportive evidence for age-specific dose recommendations.